We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+14.94%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$100M
AUM Growth
+$13.3M
Cap. Flow
+$8.34M
Cap. Flow %
8.3%
Top 10 Hldgs %
64.92%
Holding
34
New
8
Increased
8
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$6.56M
2
EVH icon
Evolent Health
EVH
+$3.29M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.85M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$2.19M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.95M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$3.7M
2
EDIT icon
Editas Medicine
EDIT
+$2.95M
3
EPZM
Epizyme, Inc
EPZM
+$2.29M
4
DXCM icon
DexCom
DXCM
+$1.7M
5
GHDX
Genomic Health, Inc.
GHDX
+$1.36M

Sector Composition

Rank Sector Weight
1 Healthcare 79.78%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$8.31M 8.27%
162,500
-7,500
-4% -$320K
AGIO icon
2
Agios Pharmaceuticals
AGIO
$1.82B
$7.86M 7.82%
187,500
+39,500
+27% +$1.95M
FMI
3
DELISTED
Foundation Medicine, Inc.
FMI
$7.28M 7.24%
390,000
+55,000
+16% +$994K
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.13M 7.1%
430,000
+325,000
+310% +$6.56M
LOXO
5
DELISTED
Loxo Oncology, Inc
LOXO
$6.95M 6.92%
300,000
+50,000
+20% +$1.24M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$6.88M 6.85%
340,000
+18,700
+6% +$340K
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$6.88M 6.85%
228,500
+39,500
+21% +$1.32M
BLUE
8
DELISTED
bluebird bio
BLUE
$5.3M 5.28%
9,457
+193
+2% +$109K
EVH icon
9
Evolent Health
EVH
$353M
$4.6M 4.58%
+239,500
New +$3.29M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$29.5B
$4.02M 4%
72,500
-17,500
-19% -$1.1M
KITE
11
DELISTED
Kite Pharma, Inc.
KITE
$3.63M 3.61%
72,500
-2,500
-3% -$123K
GNMK
12
DELISTED
GenMark Diagnostics, Inc
GNMK
$3.61M 3.59%
+415,000
New +$2.85M
VYGR icon
13
Voyager Therapeutics
VYGR
$181M
$3.54M 3.53%
322,500
-16,862
-5% -$206K
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$3.48M 3.47%
340,000
-205,000
-38% -$2.29M
CTMX icon
15
CytomX Therapeutics
CTMX
$690M
$2.39M 2.38%
234,179
-86,844
-27% -$990K
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.22M 2.21%
179,029
-296,321
-62% -$3.7M
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$2.06M 2.05%
+150,000
New +$2.19M
RXDX
18
DELISTED
Ignyta, Inc.
RXDX
$2.03M 2.02%
375,000
+265,000
+241% +$1.76M
SAGE
19
CALL
DELISTED
Sage Therapeutics
SAGE
$1.96M 1.95%
+65,000
New +$2.17M
AVXS
20
DELISTED
AveXis, Inc. Common Stock
AVXS
$1.71M 1.7%
45,000
-18,000
-29% -$609K
TSRO
21
DELISTED
TESARO, Inc.
TSRO
$1.68M 1.67%
+20,000
New +$892K
XBI icon
22
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$1.62M 1.61%
30,000
-20,000
-40% -$1.1M
BMY icon
23
Bristol-Myers Squibb
BMY
$134B
$1.54M 1.54%
21,000
– –
DXCM icon
24
DexCom
DXCM
$32.9B
$1.19M 1.18%
60,000
-100,000
-63% -$1.7M
DXCM icon
25
PUT
DexCom
DXCM
$32.9B
$1.19M 1.18%
+60,000
New +$1.02M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Casdin Capital held 34 positions worth $100M, up 15% from $87.1M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Casdin Capital deployed $8.34M of net new capital in Q2 2016, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Evolent Health: 239,500 shares worth $4.6M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $3.7M trimmed.

  • Casdin Capital's largest Q2 2016 buy was Evolent Health: 239,500 shares worth $4.6M.
  • Casdin Capital added most to Global Blood Therapeutics, Inc. in Q2 2016, an estimated $6.56M increase.
  • Casdin Capital's biggest Q2 2016 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $3.7M.
  • Casdin Capital fully exited Editas Medicine in Q2 2016, selling an estimated $2.95M.
  • Casdin Capital's ten largest holdings make up 65% of its $100M portfolio in Q2 2016.
  • Casdin Capital opened 8 new positions and closed 7 in Q2 2016.
  • Casdin Capital's portfolio value rose 15% quarter-over-quarter to $100M.

Based on Casdin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.